Navigation Links
Gliknik Adds Incyte President & CEO Paul A. Friedman to its Board of Directors

BALTIMORE, Feb. 25, 2013 /PRNewswire/ -- Gliknik Inc., a privately held biopharmaceuticals company, today announced the appointment of Incyte Corporation President and Chief Executive Officer Paul A. Friedman, M.D., to its Board of Directors. Dr. Friedman, a seasoned pharmaceutical industry executive with strong experience in management of R&D and corporate functions, joins Gliknik's board as the company is continuing to advance its pipeline of drug candidates targeting various cancers and immune disorders.

"It's an honor for us to welcome Paul to the Gliknik Board of Directors," said Gliknik CEO David S. Block. "His deep experience in pharmaceutical research, development, commercialization, and business development and his unwavering commitment to excellence bring an important perspective to Gliknik as we seek to advance and to partner our pipeline of novel therapies."

Dr. Friedman joined Incyte in 2001 as Chief Executive Officer and a Director. A biopharmaceutical company focused on discovering, developing and commercializing proprietary small molecule drugs for oncology and inflammation, Incyte developed and commercialized Jakafi® (ruxolitinib) under Dr. Friedman and has a robust product pipeline. Previously, Dr. Friedman served as President of R&D for the DuPont Merck Pharmaceutical Company, President of DuPont Pharmaceuticals Research Laboratories, and Senior Vice President at Merck Research Laboratories. Prior to his work at Merck and DuPont, Dr. Friedman was an associate professor of medicine and pharmacology at Harvard Medical School. Dr. Friedman is a diplomate of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. He received his A.B. in biology from Princeton University and his M.D. from Harvard Medical School. Dr. Friedman is also a director of Auxilium Pharmaceuticals, Inc.

"I welcome the opportunity to join the Gliknik Board of Directors and look forward to contributing to its goal of advancing and partnering the company's clinical immunomodulator and preclinical stradomer™ programs," said Dr. Friedman.

About Gliknik Inc.
Founded in 2007, Gliknik is a biopharmaceuticals company creating new therapies for patients with cancer and immune disorders. Gliknik expertise is in modulation of the immune system to fight disease. In addition to the stradomer program for autoimmune diseases, Gliknik also has commercial rights to two cancer immunomodulator drugs that are in multiple-dose clinical trials in patients with advanced head and neck cancer and in patients with advanced multiple myeloma. Learn more at


SOURCE Gliknik Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
2. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
3. Nephros Appoints John C. Houghton as President and Chief Executive Officer
4. Herb Baer Appointed President of Polar USA
5. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
6. Elsevier Appoints New President of Elsevier CPM Resource Center
7. GenWay Biotech Appoints New Vice President of Custom/OEM
8. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. Watson Names Lisa DeFrancesco Vice President, Global Investor Relations
11. Millstone Medical Outsourcing Hires New Vice President Quality
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/25/2015)... , Nov. 26, 2015  The total global healthcare industry ... over 2015-2016. Latin America has the ... , (excluding Japan ), is second with ... continues to face increased healthcare expenditure. In 2013-2014, total government ... from 43.5% in 2008-2009 to 41.2% in 2013-2014. In real ...
(Date:11/25/2015)... , Nov. 25, 2015 On Tuesday, ... federal bellwether trial against Wright Medical Technology, Inc. ... their Conserve metal-on-metal hip implant device, awarded $11 ... a two week trial and three days of ... hip device was defectively designed and unreasonably dangerous, ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... , ... The Catalent Applied Drug Delivery Institute today announced ... form selection in early phase drug development. The first of these is to ... the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating their record books ... their 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA ... rebuild lives and it’s an honor to have served all of these women.” , ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
Breaking Medicine News(10 mins):